F19.20

Other psychoactive substance dependence, uncomplicated

F19.20 is a clinical diagnosis representing a maladaptive pattern of substance use involving psychoactive agents that do not fall under the specific categories of alcohol, opioids, cannabis, sedatives, cocaine, stimulants, hallucinogens, or inhalants, or involving a combination of multiple substances where no single substance predominates. This condition is characterized by dependence, which is defined as a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use. The 'uncomplicated' designation signifies that at the time of clinical evaluation, the patient exhibits the primary features of dependence—such as a strong internal drive to use, impaired control over consumption, and physiological tolerance or withdrawal—but is not currently experiencing acute substance-induced complications like delirium, dementia, psychotic symptoms, or clinically significant mood, anxiety, or sleep disorders directly attributed to the substance. Management typically focuses on long-term recovery, psychosocial interventions, and harm reduction.

Clinical Symptoms

  • Compulsion or strong desire to consume the substance
  • Difficulty in controlling substance-taking behavior (onset, termination, or levels of use)
  • Physiological withdrawal state when substance use has ceased or been reduced
  • Evidence of tolerance, such that increased doses are required to achieve effects originally produced by lower doses
  • Progressive neglect of alternative pleasures or interests because of psychoactive substance use
  • Persisting with substance use despite clear evidence of overtly harmful consequences
  • Preoccupation with obtaining the substance, using it, or recovering from its effects
  • Reduction in social, occupational, or recreational activities
  • Narrowing of the personal repertoire of patterns of substance use (e.g., tendency to use the substance in the same way regardless of social constraints)

Common Causes

  • Dysregulation of the brain's reward system, specifically the dopaminergic pathways in the nucleus accumbens
  • Genetic predisposition or family history of substance use disorders
  • Neurobiological changes resulting from chronic exposure to psychoactive chemicals
  • Co-occurring mental health disorders such as depression, anxiety, or personality disorders (dual diagnosis)
  • Environmental factors, including low socioeconomic status, peer influence, and easy access to substances
  • Early childhood trauma, adverse childhood experiences (ACEs), or chronic stress
  • Use of poly-substances where specific classes cannot be isolated as the primary driver of dependence
  • Maladaptive coping mechanisms for dealing with emotional or physical pain

Documentation & Coding Tips

Distinguish between use, abuse, and dependence by documenting physiological or psychological symptoms.

Example: Patient meets DSM-5 criteria for dependence on synthetic cathinones, manifesting as persistent cravings and unsuccessful efforts to cut down. No acute intoxication or withdrawal symptoms present. Condition is stable on current behavioral plan. Risk adjustment: HCC 56 Drug and Alcohol Dependence. Billing focus: Chronic status and lack of acute manifestations.

Billing Focus: Documentation must specify the absence of acute manifestations like intoxication or withdrawal to support the uncomplicated suffix.

Clearly state the specific psychoactive substance if known or classify as other when not meeting criteria for opioids, alcohol, or cannabis.

Example: Diagnosis of other psychoactive substance dependence (bath salts) established. Patient demonstrates high tolerance requiring increasing dosages to achieve desired effect. No current complications. Risk adjustment: Substantiates severity of illness for mental health risk models. Billing focus: Specificity of the substance class under the F19 umbrella.

Billing Focus: Requires the provider to specify the substance class; if the substance is unspecified, F19.20 remains the most specific available code.

Document the impact of dependence on the management of co-occurring psychiatric conditions.

Example: Other psychoactive substance dependence, uncomplicated, currently interfering with the treatment of Major Depressive Disorder. Patient reports using research chemicals to self-medicate. Risk adjustment: Demonstrates complexity through co-occurring mental health disorders (dual diagnosis). Billing focus: Linking the dependence to the overall management plan.

Billing Focus: Documentation of co-occurring conditions supports higher complexity Evaluation and Management levels.

Specify the clinical status such as in remission if applicable to ensure coding accuracy.

Example: Patient with a history of other psychoactive substance dependence, now in early remission for 4 months. No active use or cravings reported. Risk adjustment: History of or remission status still impacts the risk profile but may map differently than active dependence. Billing focus: Longitudinal care tracking.

Billing Focus: If the patient is in remission, F19.21 (in remission) should be used instead of F19.20.

Use standardized screening tools to quantify the severity of the dependence.

Example: DAST-10 score of 8 indicates severe level of drug-related problems. Patient diagnosed with other psychoactive substance dependence, uncomplicated. No medical complications at this time. Risk adjustment: Provides objective evidence for the dependence diagnosis. Billing focus: Quantitative assessment supports medical necessity for intensive counseling.

Billing Focus: Results of standardized tests provide clinical evidence to support the diagnosis during audits.

Relevant CPT Codes

Related Diagnoses

Hierarchy